Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

NCT01731652 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma in Situ
Non Muscle Invasive Bladder Cancer

Interventions

DRUG: TMX-101

Sponsor

Telormedix SA